Status:

COMPLETED

Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients

Lead Sponsor:

Lower Saxony Center for Nephrology

Conditions:

DNA Virus Infection

Herpesviridae Infections

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Study Phase: IV Study Type: Open-label, multicenter, randomised clinical trial with two arms stratified for an intensified immunosuppressive regimen in patients at high risk for acute rejection. Stu...

Detailed Description

Disease Background: More than 60 % of adult people are asymptomatically infected with cytomegalovirus (CMV). Due to immunosuppressive therapy, renal graft recipients are at risk for CMV infection and ...

Eligibility Criteria

Inclusion

  • Kidney transplant recipients after living or postmortal donation
  • CMV seropositive donor or recipient of the kidney transplant: D+/R-, D+/R+ or D-/R+
  • Laboratory parameters: 50.000/ml thrombocytes and/or 1000/ml neutrophils
  • Immunosuppression including MMF
  • Main

Exclusion

  • Woman who are pregnant, breastfeeding or using unreliable birth control methods
  • Forbidden concomitant medications during the 12 month observation period of the study are:
  • Virustatic drugs, active against CMV: Foscarnet, Cidofovir (HPMPC), Acyclovir, Valaciclovir, Famciclovir/Penciclovir, Lobucavir, Antisense compound
  • Antimetabolites: Fluorouracil, Mercaptopurine, Methotrexate, Thioguanine, Hydroxurea
  • Alkylating substances: Busulfan, Carmustine, Chlorambucil, Cisplatin, Cyclophosphamide, Dacarbazine (DTIC), Lomustine, Mechlormethamine, Melphalan, Streptozotocin, Tiothepa, Uracil mustard
  • anti CMV immunoglobulins (except in the case of signs of CMV infection) such as anti CMV hyperimmunoglobulins and immunoglobulins
  • Known hypersensitivity to ganciclovir
  • Patients with active CMV infection or positive viraemia at randomization
  • Severe gastro-intestinal diseases which may interfere with the oral resorption of ganciclovir
  • Conversion of immunosuppression (Replacement of MMF)
  • Participation in another clinical drug trial

Key Trial Info

Start Date :

August 1 2000

Trial Type :

INTERVENTIONAL

End Date :

October 1 2003

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT00373165

Start Date

August 1 2000

End Date

October 1 2003

Last Update

September 13 2006

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients | DecenTrialz